Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2010Alimentary Pharmacology & TherapeuticsOpen Access

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSimon LichtigerSt. Joseph HospitalDBDG BinionDWDouglas C. WolfAtlanta Gastroenterology Associates

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lichtiger et al. (2010) studied this question.

synapsesocial.com/papers/6a76278df1e99ff85ab23e45https://doi.org/10.1111/j.1365-2036.2010.04466.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Permanent Work Disability in Crohn's Disease2008 · 97 citations
  2. 2Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab‐treated and naïve patients2008 · 40 citations
  3. 3Adalimumab for the treatment of fistulas in patients with Crohn’s disease2009 · 363 citations
  4. 4The epidemiology and natural history of Crohn’s disease in population‐based patient cohorts from North America: a systematic review2002 · 466 citations
  5. 5European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis2006 · 511 citations